Table 4.

Most common non-serious adverse events

		Intravenous antibiotic therapy (n=126)		Oral antibiotic therapy (n=146)		Total (n=272)
		Events	Participants	Events	Participants	Events	Participants
Any non-serious adverse event*		126	60 (48%)	136	72 (49%)	262	132 (49%)
Most common non-serious adverse events†
	Cough	26	22 (17%)	28	23 (16%)	54	45 (17%)
	Upper respiratory tract infection	15	11 (9%)	3	2 (1%)	18	13 (5%)
	Productive cough	5	5 (4%)	8	8 (5%)	13	13 (5%)

Data are n or n (%).

^*Nine additional adverse events were reported by nine participants in the intravenous antibiotic therapy group and five adverse events from five participants in the oral antibiotic therapy group but have not been included here as they were the event of interest for the primary outcome (P aeruginosa isolation) so should not have been reported as an adverse event. Three additional adverse events were reported by three participants in the oral antibiotic therapy group but have not been included here as they contributed to the analysis of the outcome number of pulmonary exacerbations.

^†Reported by at least 5% of participants in either treatment group.